EBITDA: Income before interest, taxes, depreciation and amortization.
Madrigal Pharmaceuticals, Inc. (MDGL) had EBITDA of $-116.28M for the most recently reported fiscal quarter, ending 2023-12-31.
Income Statement Financials | |
-- |
|
$-112.19M |
|
-- |
|
-- |
|
$117.18M |
|
$-117.18M |
|
$4.98M |
|
$-112.19M |
|
$-112.19M |
|
$-112.19M |
|
$-112.19M |
|
$-112.19M |
|
$-112.19M |
|
$-117.18M |
|
EBITDA |
$-116.28M |
18.69M |
|
18.69M |
|
$-5.73 |
|
$-5.73 |
|
Balance Sheet Financials | |
$637.28M |
|
$1.55M |
|
$3.27M |
|
$640.55M |
|
$118.55M |
|
$115.48M |
|
$116.67M |
|
$235.21M |
|
$405.33M |
|
$405.33M |
|
$405.33M |
|
19.88M |
|
Cash Flow Statement Financials | |
$-324.23M |
|
$-502.52M |
|
$595.12M |
|
$331.55M |
|
$99.92M |
|
$-231.63M |
|
$49.73M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
5.38 |
|
-- |
|
-- |
|
0.22 |
|
0.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-325.71M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-27.68% |
|
-27.68% |
|
-17.52% |
|
-21.54% |
|
$20.39 |
|
$-17.43 |
|
$-17.35 |